Clinigen, the Burton-based pharmaceutical products and services company, has received a non-binding indicative proposal from Triton Investment Management Limited for a possible offer for the entire issued and to be issued ordinary share capital of the business.
The board of Clinigen said it is in advanced discussions with Triton regarding the proposal, but there can be no certainty that any firm offer will be made for the company, nor as to the terms on which any firm offer might be made.
Triton is an investment firm focused on mid-market businesses. They sit within one of four sectors: industrial tech, services, consumer and healthcare.
Triton is required, by no later than 30 December, to announce a firm intention to make an offer for Clinigen or that it does not intend to make an offer.
